Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors
about
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Haemopoietic stem cell transplantation from unrelated donors.Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT).Unrelated donor hematopoietic transplantation.Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.A clinical role for peripheral blood lymphocyte infusions and perspectives on collection.Cellular therapy following allogeneic stem-cell transplantation.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.The development of novel immunotherapeutic approaches in multiple myeloma.Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia.Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
P2860
Q33357697-537BBEA3-553C-42AA-B6DD-65283065E872Q33656177-033DA60E-48B8-4558-BE12-532C5975CAF0Q33994342-9A5E893D-D183-4150-B95B-31F9A09057B7Q34089112-E1A09032-FF0A-492F-A697-5ABF928A008FQ34135678-C315C5FC-6424-4CF7-8406-817065D9CE18Q34326698-4474AAD7-0852-49B3-9E6B-A8C7D5D5C1FBQ34573989-C565DDAD-E84D-4086-936F-BEB346B318C7Q35201910-7740014D-36D1-4AE0-8936-9FEF134D5B29Q36612643-C4E554EA-9DB6-4AC9-AD6A-9D5F467CB2C0Q36689152-7B216C68-4549-4DFC-A2EE-86EE576D34DEQ37008223-051894E1-3F22-4CDD-AD53-1306C9F7B91BQ37132883-817E7E30-B3A7-4F76-BB9B-7392E66710B2Q39712243-AE0E660D-A982-484E-9117-2E6957FF799FQ40049548-97663091-D11B-426E-BA82-320216AA4844Q44723592-5BAEE6F0-3D60-46F7-B90D-9299B91235D0
P2860
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors
description
im Mai 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 1998
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 1998
@uk
name
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@en
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@nl
type
label
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@en
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@nl
prefLabel
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@en
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@nl
P2093
P50
P921
P356
P1476
Adoptive immunotherapy for rel ...... g and matched unrelated donors
@en
P2093
Apperley J
Blackwell J
Goldman JM
van Rhee F
P2888
P304
P356
10.1038/SJ.BMT.1701224
P407
P577
1998-05-01T00:00:00Z